We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ESMO welcomes the adoption of the Clinical Trials Regulation by the E.U.

ESMO welcomes the adoption of the Clinical Trials Regulation by the E.U.

June 17, 2014
CenterWatch Staff

The European Society for Medical Oncology (ESMO) has welcomed the adoption of the Clinical Trials Regulation by the E.U.

The new framework acknowledges the importance of using data stored for a clinical trial beyond the end of the study itself, for research purposes. Practically speaking, when a patient gives consent for a clinical trial, he/she can easily give a one-time consent for data to be used beyond the trial, for medical research purposes, still with the possibility to withdraw it at any time.

"The adoption by the E.U. represents an important milestone, according to ESMO, in support of our efforts to safeguard medical research in Europe," said Paolo Casali, ESMO public policy committee chair.

The regulation, which now will become law in all member states, provides a harmonized framework for conducting clinical trials, focusing on trial data transparency, streamlined application process, strict approval timelines and reduced bureaucracy for multi-country studies.

"The novel Clinical Trials Regulation represents Europe's unique chance to make Europe competitive, attractive and visionary in conducting the fundamental trials necessary for our fight against cancer," said Christian Dittrich, ESMO faculty coordinator. "It is equipped to ensure that medical research will be able to continue in a smooth manner, for the ultimate benefit of patients."

"Patients need more progress in research to develop new, effective and safe therapies at a faster pace; with the new regulation, European cancer research will become more patient-centric," said Jan Geissler, CML Advocates Network.

Europe Ethics/Regulatory

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing